The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity

Diabetologia

Volumn 48, Issue 10, 2005, Pages 2162-2169

  Sanchez Quesada J L ^a   Benitez S ^a   Perez A ^a   Wagner, A M ^a   Rigla, M ^a   Carreras, G ^a   Vila, L ^a   Camacho, M ^a   Arcelus, R ^a   Ordonez Llanos J ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherosclerosis; Electronegative low density lipoprotein; Inflammation; Type 1 diabetes mellitus

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; FATTY ACID; FRUCTOSAMINE; GLYCOSYLATED PROTEIN; INSULIN; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME ACTIVITY; GLYCOSYLATION; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIPID COMPOSITION; MAJOR CLINICAL STUDY; OXIDATION; PRIORITY JOURNAL; PROTEIN ANALYSIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOPROTEINS; BLOOD GLUCOSE; CELLS, CULTURED; CHEMISTRY, PHYSICAL; CHEMOKINES; DIABETES MELLITUS, TYPE 1; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPIDS; LIPOPROTEINS, LDL; MALONDIALDEHYDE; OXIDATION-REDUCTION; TRANSCRIPTION FACTORS;

EID: 26244452534     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1899-8     Document Type: Article

References (39)

1. The DCCT Research Group (1992) Lipid and lipoprotein levels in patients with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial (DCCT) experience. Diabetes Care 15:886-894
2. Assmann G, Schulte H (1988) The prospective cardiovascular Munster (PROCAM) study. Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116:1713-1724
3. Navab M, Berliner JA, Watson AD et al (1996) The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 16:831-842
4. Scheffer PG, Henry RMA, Wever EJM et al (2004) LDL oxidative modifications in well- or moderately controlled type 2 diabetes. Diabetes/Metab Res Rev 20:298-304
5. Kim HJ, Kurup IV (1982) Nonenzymatic glycosylation of human low density lipoprotein; evidence for in vivo and in vitro glycosylation. Metabolism 31:348-352
6. Sobenin IA, Tertov W, Koschinski T et al (1993) Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 100:41-54
7. Caixàs A, Ordóñez-Llanos J, de Leiva A, Payés A, Homs R, Pérez A (1997) Improvement of glycemic control in diabetes decreases the atherogenic small dense LDL particles. Diabetes 46:1207-1213
8. Avogaro P, Bittolo-Bon G, Cazzolato G (1988) Presence of a modified low density lipoprotein in humans. Arteriosclerosis 8:79-87
9. Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J (2004) Electronegative low-density lipoprotein. Curr Opin Lipidol 15:329-335
10. Sánchez-Quesada JL, Benítez S, Franco M, Otal C, Blanco-Vaca F, Ordóñez-Llanos J (2002) Density distribution of electronegative LDL (LDL(-)) in normolipemic and hyperlipemic subjects. J Lipid Res 43:699-705
11. Benítez S, Ordóñez-Llanos, Franco M et al (2004) Effect of simvastatin in familial hypercholesterolemia on the affinity of charge-differing low-density lipoprotein subfractions to the low-density lipoprotein receptor. Am J Cardiol 93:414-420
12. Hodis HN, Kramsch DM, Avogaro P et al (1994) Biochemical and cytotoxic characteristics of an in vivo circulating oxidised low-density lipoprotein (electronegative LDL). J Lipid Res 35:669-677
13. Demuth K, Myara I, Chappey B et al (1996) A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 16:773-783
14. Chen CH, Jiang T, Yang JH et al (2003) Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107:2102-2108
15. de Castellarnau C, Sánchez-Quesada JL, Benítez S et al (2000) Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol 20:2281-2287
16. Sánchez-Quesada JL, Camacho M, Antón R, Benítez S, Vila L, Ordóñez-Llanos J (2003) Electronegative LDL of FH subjects. Chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 166:261-270
17. Ziouzenkova O, Asatryan L, Sahady D et al (2003) Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 278:39874-39881
18. Sánchez-Quesada JL, Otal-Entraigas C, Franco M et al (1999) Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with familial hypercholesterolemia. Am J Cardiol 84:655-659
19. Ziouzenkova O, Asatryan L, Akmal M et al (1999) Oxidative cross-linking of apoB100 and hemoglobin results in low density lipoproteins modification in blood. J Biol Chem 27:18916-18924
20. Sánchez-Quesada JL, Pérez A, Caixàs A et al (1996) Electronegative low-density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. Diabetologia 39:1469-1476
21. Sánchez-Quesada JL, Pérez A, Caixàs A et al (2001) Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab 86:3243-3249
22. Moro E, Zambón C, Pianetti S, Cazzolato G, Pais M, Bittolo Bon G (1998) Electronegative low density lipoprotein subform is increased in type 2 (non-insulin-dependent) microalbuminuric patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol 35:161-164
23. Moro E, Alessandrini P, Zambón C et al (1999) Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 16:663-669
24. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057
25. Sánchez-Quesada JL, Ortega H, Payés-Romero A et al (1997) LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects. Atherosclerosis 132:207-213
26. Fukunaga K, Suzuki T, Takama K (1993) Highly sensitive high-performance liquid chromatography for the measurement of malondialdehyde in biological samples. J Chromatogr 621:77-81
27. Khoo J, Miller E, McLaughlin P, Steinberg D (1988) Enhanced macrophage uptake of low-density lipoprotein after self-aggregation. Arteriosclerosis 8:348-358
28. Benítez S, Sánchez-Quesada JL, Ribas V et al (2003) Platelet-activating factor acetylhydrolase is mainly associated with electronegative LDL subfraction. Circulation 108:92-96
29. Lyons TJ (1991) Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabet Med 8:411-419
30. Gambino R, Giunti S, Uberti B, Perin PC, Pagano G, Cassader M (2003) LDL electronegativity is enhanced in type 1 diabetes. Diabetes Care 26:2214-2215
31. Hermann M, Gneimer B (1992) Altered susceptibility to in vitro oxidation of LDL in LDL complexes and LDL aggregates. Arterioscler Thromb 12:1503-1506
32. Noto H, Hara M, Karasawa K et al (2003) Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 23:829-835
33. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF (1996) LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 45:762-767
34. Feillet C, Roche B, Tauveron I et al (1998) Susceptibility to oxidation and physicochemical properties of LDL in insulin-dependent diabetics. Atherosclerosis 136:405-407
35. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
36. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W (2004) Fluvastatin slow-release lowers platelet-activating factor acetylhydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89:1153-1159
37. Serban M, Tanaseanu C, Kosaka T et al (2002) Significance of platelet-activating factor acetylhydrolase in patients with non-insulin dependent (type 2) diabetes mellitus. J Cell Mol Med 6:643-647
38. Scholin A, Siegbahn A, Lind L et al (2004) CRP and IL-6 concentrations are associated with poor glycemic control despite preserved B-cell function during the first year after diagnosis of type 1 diabetes. Diabetes/Metab Res Rev 20:205-210
39. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M (2004) Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 112:378-382